• What is Veklury?

  Veklury is a prescription medicine that is investigational for use for the treatment of COVID-19 in children weighing 8 pounds (3.5 kg) to less than 88 pounds (40 kg) or children less than 12 years of age weighing at least 8 pounds (3.5 kg) with positive results of direct SARS-CoV-2 viral testing, who are:

  • hospitalized, or
  • not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

  Veklury is investigational for this use because it is still being studied and there is limited information about the safety and effectiveness of using Veklury for the treatment of COVID-19 in this population.

  Veklury is an FDA-approved prescription medicine used to treat COVID-19 in adults and children (12 years of age and older and weighing at least 88 pounds (40 kg), with positive results of direct SARS-CoV-2 viral testing, who are:

  • hospitalized, or
  • not hospitalized and have mild-to-moderate COVID-19, and at high risk for progression to severe COVID-19, including hospitalization or death.
• What should I tell my healthcare provider before my child receives Veklury?
• How will my child receive Veklury?
• Who should generally not receive Veklury?
• What are the important possible side effects of Veklury?
• References

These FAQs provide a summary of the most important information about Remdesivir. If you would like more information or have any questions, talk to your healthcare provider.

• What is the most important information I should know about Paxlovid?

  Paxlovid can interact with other medicines causing severe or life-threatening side effects or death. It is important to know the medicines that should not be taken with Paxlovid.

  Do not take Paxlovid if:

  • you are taking any of the following medicines:

  alfuzosin amiodarone apalutamide carbamazepine colchicine dihydroergotamine dronedarone eletriptan eplerenone ergotamine finerenone flecainide flibanserin ivabradine

  lomitapide lovastatin lumacaftor/ivacaftor lurasidone methylergonovine midazolam (oral) naloxegol phenobarbital phenytoin pimozide primidone propafenone quinidine

  ranolazine rifampin rifapentine St. John’s Wort (hypericum perforatum) sildenafil (Revatio®) for pulmonary arterial hypertension silodosin simvastatin tolvaptan triazolam ubrogepant voclosporin

  These are not the only medicines that may cause serious or life-threatening side effects if taken with Paxlovid. Paxlovid may increase or decrease the levels of multiple other medicines. It is very important to tell your healthcare provider about all of the medicines you are taking because aliitional laboratory tests or changes in the dose of your other medicines may be necessary during treatment with Paxlovid. Your healthcare provider may also tell you about specific symptoms to watch out for that may indicate that you need to stop or decrease the dose of some of your other medicines.

  • you are allergic to nirmatrelvir, ritonavir, or any of the ingredients in Paxlovid. See "What are the important possible side effects of Paxlovid?" for signs and symptoms of allergic reactions.
• What is Paxlovid?
• What should I tell my healthcare provider before I take Paxlovid?
• How do I take Paxlovid?
• What are the important possible side effects of Paxlovid?
• What other treatment choices are there?
• What if I am pregnant or breastfeeding?
• How should I store Paxlovid?
• References

These FAQs provide a summary of the most important information about Nirmatrelvir and Ritonavir. The drug should not be used for a condition other than that for which it is prescribed. Do not give it to other people, even if they have the same symptoms that you have. It may harm them. If you would like more information or have any questions, talk to your healthcare provider.

• What is the most important information I should know about Lagevrio?

  Lagevrio may cause serious side effects, including:

  • Lagevrio may cause harm to your unborn baby. It is not known if Lagevrio will harm your baby if you take Lagevrio during pregnancy.
    • Lagevrio is not recommended for use in pregnancy.
    • Lagevrio has not been studied in pregnancy. Lagevrio was studied in pregnant animals only. When Lagevrio was given to pregnant animals, Lagevrio caused harm to their unborn babies.
    • You and your healthcare provider may decide that you should take Lagevrio during pregnancy if there are no other COVID-19 treatment options approved or authorized by the FDA that are accessible or clinically appropriate for you.
    • If you and your healthcare provider decide that you should take Lagevrio during pregnancy, you and your healthcare provider should discuss the known and potential benefits and the potential risks of taking Lagevrio during pregnancy.

  For individuals who are able to become pregnant:

  • You should use a reliable method of birth control (contraception) consistently and correctly during treatment with Lagevrio and for 4 days after the last dose of Lagevrio. Talk to your healthcare provider about reliable birth control methods.
  • Before starting treatment with Lagevrio your healthcare provider may do a pregnancy test to see if you are pregnant before starting treatment with Lagevrio.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Lagevrio.
• What is Lagevrio?
• What should I tell my healthcare provider before I take Lagevrio?
• How do I take Lagevrio?
• What are the important possible side effects of Lagevrio?
• References

These FAQs provide a summary of the most important information about Molnupiravir. If you would like more information or have any questions, talk to your healthcare provider.

• What is casirivimab and imdevimab?

  Casirivimab and imdevimab are investigational medicines used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents (12 years of age and older who weigh at least 88 pounds (40 kg)), and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.

  Casirivimab and imdevimab are investigational because they are still being studied. There is limited information known about the safety and effectiveness of using casirivimab and imdevimab to treat people with COVID-19.

  On Jan. 24, 2022, HHS and FDA announced that REGEN-COV is not currently authorized for use in the US because they are not considered effective against the Omicron variant.

• What should I tell my health care provider before I receive casirivimab and imdevimab?
• How will I receive casirivimab and imdevimab?
• What are the important possible side effects of casirivimab and imdevimab?
• What if I am pregnant or breastfeeding?
• References

These FAQs provide a summary of the most important information about Casirivimab and Imdevimab Injection. If you would like more information or have any questions, talk to your healthcare provider.

• What is sotrovimab?

  Sotrovimab is an investigational medicine used to treat mild-to-moderate symptoms of COVID-19 in adults and children (12 years of age and older weighing at least 88 pounds [40 kg]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk of progression to severe COVID-19, including hospitalization or death. Sotrovimab is investigational because it is still being studied. There is limited information about the safety and effectiveness of using sotrovimab to treat people with mild-to-moderate COVID-19.

  On April 5, 2022, HHS and the FDA announced that sotrovimab is not currently authorized in the US because they are not considered effective against the BA.2 variant.

• What should I tell my healthcare provider before I receive sotrovimab?
• How will I receive sotrovimab?
• What are the important possible side effects of sotrovimab?
• What if I am pregnant or breastfeeding?
• References

These FAQs provide a summary of the most important information about Sotrovimab Injection. If you would like more information or have any questions, talk to your healthcare provider.

• What are bamlanivimab and etesevimab?

  Bamlanivimab and etesevimab are investigational medicines used to treat mild to moderate symptoms of COVID19 in adults and adolescents (12 years of age and older who weigh at least 88 pounds (40 kg)), and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization. Bamlanivimab and etesevimab are investigational because they are still being studied. There is limited information known about the safety or effectiveness of using bamlanivimab and etesevimab to treat people with COVID-19.

  On Jan. 24, 2022, HHS and FDA announced that BAM/ETE is not currently authorized for use in the US because they are not considered effective against the Omicron variant.

• What should I tell my healthcare provider before I receive bamlanivimab and etesevimab?
• How will I receive bamlanivimab and etesevimab?
• What are the important possible side effects of bamlanivimab and etesevimab?
• What if I am pregnant or breastfeeding?
• References

These FAQs provide a summary of the most important information about Bamlanivimab and Etesevimab Injection. If you would like more information or have any questions, talk to your healthcare provider.

• What is bebtelovimab?

  Bebtelovimab is an investigational medicine used for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and children (12 years of age and older weighing at least 88 pounds [40 kg]):

  • with positive results of direct SARS-CoV-2 viral testing, and
  • who are at high risk for progression to severe COVID-19, including hospitalization or death, and
  • for whom other COVID-19 treatment options approved or authorized by FDA are not available or clinically appropriate.

  There is limited information known about the safety and effectiveness of using bebtelovimab for the treatment of mild-to-moderate COVID-19.

  The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to make bebtelovimab available during the COVID-19 pandemic. Bebtelovimab is not an FDA-approved medicine in the United States.

  Bebtelovimab is not authorized for use in people who:

  • are likely to be infected with a SARS-CoV-2 variant that is not able to be treated by bebtelovimab based on the circulating variants in your area (ask your health care provider about FDA and CDC’s latest information on circulating variants by geographic area), or
  • are hospitalized due to COVID-19, or
  • require oxygen therapy and/or respiratory support due to COVID-19, or
  • require an increase in baseline oxygen flow rate and/or respiratory support due to COVID19 and are on chronic oxygen therapy and/or respiratory support due to underlying non COVID-19 related comorbidity.
• What should I tell my healthcare provider before I or my child receive bebtelovimab?
• How will I or my child receive bebtelovimab?
• What are the important possible side effects of bebtelovimab?
• References

These FAQs provide a summary of the most important information about Bebtelovimab Injection. If you would like more information or have any questions, talk to your healthcare provider.

• What is the most important information I should know about Olumiant?

  Olumiant may cause serious side effects, including:

  1. Serious infections.
  Olumiant is a medicine that affects your immune system. Olumiant can lower the ability of your immune system to fight infections. Some people have had serious infections while taking Olumiant, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.

  • Your healthcare provider should test you for TB before starting treatment with Olumiant for rheumatoid arthritis or alopecia areata.
  • Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with Olumiant.

  You should not start taking Olumiant if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles.

  Before starting Olumiant, tell your healthcare provider if you:

  • are being treated for an infection
  • have an infection that does not go away or that keeps coming back
  • have diabetes, chronic lung disease, HIV, or a weak immune system. People with these conditions have a higher chance for infections
  • have TB or have been in close contact with someone with TB
  • have had shingles (herpes zoster)
  • have had hepatitis B or C
  • live or have lived, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use Olumiant. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.
  • think you have an infection or have symptoms of an infection such as:
    • fever, sweating, or chills
    • shortness of breath
    • warm, red, or painful skin or sores on your body
    • feeling tired
    • muscle aches
    • blood in your phlegm
    • diarrhea or stomach pain
    • cough
    • weight loss
    • burning when you urinate or urinating more often than normal

  After starting Olumiant, call your healthcare provider right away if you have any symptoms of an infection. Olumiant can make you more likely to get infections or, make worse any infection that you have. If you get a serious infection, your healthcare provider may stop your treatment with Olumiant until your infection is controlled.

  2. Increased risk of death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called Janus kinase (JAK) inhibitors. Olumiant is a JAK inhibitor medicine.

  3. Cancer and immune system problems.
  Olumiant may increase your risk of certain cancers by changing the way your immune system works.

  • Lymphoma and other cancers including skin cancers can happen in people taking Olumiant. People taking a medicine in the class of medicines called Janus kinase (JAK) inhibitors have a higher risk of certain cancers including lymphoma and lung cancer, especially if you are a current or past smoker.
  • Tell your healthcare provider if you have ever had any type of cancer. Follow your healthcare provider's advice about having your skin checked for skin cancer during treatment with Olumiant.

  4. Increased risk of major cardiovascular events such as heart attack, stroke or death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors, especially if you are a current or past smoker.
  Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Olumiant, including:

  • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw, or stomach
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded
  • weakness in one part or on one side of your body
  • slurred speech

  5. Blood Clots.
  Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) and arteries (arterial thrombosis) can happen in some people taking Olumiant. This may be life-threatening and cause death. Blood clots in the veins of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a medicine in the class of medicines called Janus kinase (JAK) inhibitors.

  • Tell your healthcare provider if you have had blood clots in the veins of your legs or lungs in the past.
  • Stop taking Olumiant and tell your healthcare provider or get emergency help right away if you have any signs and symptoms of blood clots during treatment with Olumiant, including: swelling, pain or tenderness in the leg, sulien unexplained chest pain, or shortness of breath.

  6. Allergic Reactions.
  Symptoms such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, that may mean you are having an allergic reaction have been seen in people taking Olumiant. Some of these reactions were serious. If any of these symptoms occur during treatment with Olumiant, stop taking Olumiant and get emergency help right away.

  7. Tears (perforation) in the stomach or intestines.

  • Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking Olumiant can get tears in their stomach or intestines. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.
  • Tell your healthcare provider right away if you have fever and stomach-area pain that does not go away, and a change in your bowel habits.

  8. Changes in certain laboratory test results.
  Your healthcare provider should do blood tests before you start taking Olumiant and while you take Olumiant to check for the following:

  • low neutrophil and lymphocyte counts. Neutrophils and lymphocytes are types of white blood cells that help the body fight off infections.
  • low red blood cell counts. This may mean that you have anemia, which may make you feel weak and tired.
  • increased cholesterol levels. If you are being treated for rheumatoid arthritis or alopecia areata, your healthcare provider should do blood tests to check your cholesterol levels approximately 12 weeks after you start taking Olumiant, and as needed.
  • elevated liver enzymes. Liver enzymes help to tell if your liver is functioning normally. Elevated liver enzymes may indicate that your healthcare provider needs to do aliitional tests on your liver.

  You should not take Olumiant if your lymphocyte count, neutrophil count, or red blood cell count is too low or your liver tests are too high. Your healthcare provider may stop your Olumiant treatment for a period of time if needed because of changes in these blood test results.

  See "What are the possible side effects of Olumiant?" for more information about side effects.

• What is Olumiant?
• What should I tell my healthcare provider before taking Olumiant?
• How should I take Olumiant?
• What are the possible side effects of Olumiant?
• How should I store Olumiant?
• References

These FAQs provide a summary of the most important information about Baricitinib. The drug should not be used for a condition other than that for which it is prescribed. Do not give it to other people, even if they have the same symptoms that you have. It may harm them. If you would like more information or have any questions, talk to your healthcare provider.

• What is the most important information I should know about Actemra?

  Actemra can cause serious side effects including:

  • Serious Infections. Actemra is a medicine that affects your immune system. Actemra can lower the ability of your immune system to fight infections. Some people have serious infections while taking Actemra, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should assess you for TB before starting Actemra (except if you have COVID-19).

  If you have COVID-19, your healthcare provider should monitor you for signs and symptoms of new infections during and after treatment with Actemra.

  Your healthcare provider should monitor you closely for signs and symptoms of TB during treatment with Actemra.

  • You should not start taking Actemra if you have any kind of infection unless your healthcare provider says it is okay.

  Before starting Actemra, tell your healthcare provider if you:

  • think you have an infection or have symptoms of an infection, with or without a fever, such as:
    • sweating or chills
    • shortness of breath
    • warm, red, or painful skin or sores on your body
    • feel very tired
    • muscle aches
    • blood in phlegm
    • diarrhea or stomach pain
    • cough
    • weight loss
    • burning when you urinate or urinating more often than normal

  • are being treated for an infection.
  • get a lot of infections or have infections that keep coming back.
  • have diabetes, HIV, or a weak immune system. People with these conditions have a higher chance for infections.
  • have TB, or have been in close contact with someone with TB.
  • live or have lived, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections (histoplasmosis, coccidiomycosis, or blastomycosis). These infections may happen or become more severe if you use Actemra. Ask your healthcare provider, if you do not know if you have lived in an area where these infections are common.
  • have or have had hepatitis B.

  After starting Actemra, call your healthcare provider right away if you have any symptoms of an infection. Actemra can make you more likely to get infections or make worse any infection that you have.

  If you have COVID-19, your healthcare provider should monitor you for signs and symptoms of new infections during and after treatment with Actemra.

  • Tears (perforation) of the stomach or intestines.
    • Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking Actemra get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.
    • Tell your healthcare provider right away if you have fever and stomach-area pain that does not go away, and a change in your bowel habits.
  • Liver problems (Hepatotoxicity): Some people have experienced serious life-threatening liver problems, which required a liver transplant or led to death. Your healthcare provider may tell you to stop taking Actemra if you develop new or worse liver problems during treatment with Actemra. Tell your healthcare provider right away if you have any of the following symptoms:
    • feeling tired (fatigue)
    • lack of appetite for several days or longer (anorexia)
    • yellowing of your skin or the whites of your eyes (jaundice)
    • abdominal swelling and pain on the right side of your stomach-area
    • light colored stools
    • weakness
    • nausea and vomiting
    • confusion
    • dark "tea-colored" urine
  • Changes in certain laboratory test results. Your healthcare provider should do blood tests before you start receiving Actemra. If you have rheumatoid arthritis (RA), giant cell arteritis (GCA), or systemic sclerosis-interstitial lung disease (SSc-ILD) your healthcare provider should do blood tests every 4 to 8 weeks after you start receiving Actemra for the first 6 months and then every 3 months after that. If you have polyarticular juvenile idiopathic arthritis (PJIA) you will have blood tests done every 4 to 8 weeks during treatment. If you have systemic juvenile idiopathic arthritis (SJIA) you will have blood tests done every 2 to 4 weeks during treatment. These blood tests are to check for the following side effects of Actemra:Your healthcare provider will determine how often you will have follow-up blood tests. Make sure you get all your follow-up blood tests done as ordered by your healthcare provider.
    You should not receive Actemra if your neutrophil or platelet counts are too low or your liver function tests are too high.
    Your healthcare provider may stop your Actemra treatment for a period of time or change your dose of medicine if needed because of changes in these blood test results.
    • low neutrophil count. Neutrophils are white blood cells that help the body fight off bacterial infections.
    • low platelet count. Platelets are blood cells that help with blood clotting and stop bleeding.
    • increase in certain liver function tests.
    • increase in blood cholesterol levels. You may also have changes in other laboratory tests, such as your blood cholesterol levels. Your healthcare provider should do blood tests to check your cholesterol levels 4 to 8 weeks after you start receiving Actemra.
  • Cancer. Actemra may increase your risk of certain cancers by changing the way your immune system works. Tell your healthcare provider if you have ever had any type of cancer.

  See "What are the possible side effects with Actemra?" for more information about side effects.

• What is Actemra?
• Who should not receive Actemra?
• What should I tell my healthcare provider before receiving Actemra?
• How will I receive Actemra?
• What are the possible side effects with Actemra?
• References

These FAQs provide a summary of the most important information about Tocilizumab Injection. If you would like more information or have any questions, talk to your healthcare provider.

• What is Spikevax and Moderna COVID-19 vaccine?

  Spikevax is an mRNA vaccine for use in people 12 years of age and older to protect against COVID-19. mRNA vaccines use mRNA created in a laboratory to teach our cells how to make a protein—or even just a piece of a protein—that triggers an immune response inside our bodies. The mRNA from the vaccines is broken down within a few days after vaccination and discarded from the body.

  The Moderna COVID-19 vaccine is a vaccine for use in individuals 6 months through 11 years of age to prevent COVID-19. The FDA has authorized the emergency use of the Moderna COVID-19 vaccine under an EUA.

  The 2023-2024 formula is made the same way as the Moderna COVID-19 Vaccine (Original monovalent) and Moderna COVID-19 Vaccine, Bivalent, but it encodes the spike protein of SARS-CoV-2 Omicron variant lineage XBB.1.5 (Omicron XBB.1.5).

  The vaccine may not protect all people who receive the vaccine. It does not contain SARS-CoV-2, the virus that causes COVID-19. Therefore, it cannot give you COVID-19.

• Who should not get Spikevax?
• What should I tell my healthcare provider?
• How is the vaccine given?
• What are the risks of Spikevax?
• What are the ingredients in Spikevax?
• References

These FAQs provide a summary of the most important information about COVID-19 Vaccine, mRNA (Moderna). If you would like more information or have any questions, talk to your healthcare provider.

• What is Comirnaty and Pfizer-BioNTech COVID-19 vaccine?

  Comirnaty is an mRNA vaccine for use in people 12 years of age and older to protect against COVID-19. mRNA vaccines use mRNA created in a laboratory to teach our cells how to make a protein—or even just a piece of a protein—that triggers an immune response inside our bodies. The mRNA from the vaccines is broken down within a few days after vaccination and discarded from the body.

  The Pfizer-BioNTech COVID-19 vaccine is a vaccine for use in individuals 6 months through 11 years of age to prevent COVID-19. The FDA has authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine under an EUA.

  The 2023-2024 formula is made the same way as Pfizer-BioNTech COVID-19 Vaccine (Original monovalent) and Pfizer-BioNTech COVID-19 Vaccine, Bivalent, but it encodes the spike protein of SARS-CoV-2 Omicron variant lineage XBB.1.5 (Omicron XBB.1.5).

  The vaccine may not protect all people who receive the vaccine. It does not contain SARS-CoV-2, the virus that causes COVID-19. Therefore, it cannot give you COVID-19.

• Who should not get Comirnaty?
• What should I tell my vaccination provider before getting Comirnaty?
• How is the vaccine given?
• What are the possible risks of Comirnaty?
• What are the ingredients in Pfizer-BioNTech COVID-19 vaccines?
• References

These FAQs provide a summary of the most important information about COVID-19 Vaccine, mRNA (Pfizer-BioNTech). If you would like more information or have any questions, talk to your healthcare provider.

• What is the Janssen COVID-19 vaccine?

  The J&J/Janssen COVID-19 Vaccine is an unapproved vaccine that may prevent COVID-19. J&J/Janssen COVID-19 vaccine has expired and is no longer available for use in the United States as of May 6, 2023.

  Viral vector vaccines use a harmless, modified version of a different virus (a vector virus), and not the virus that causes COVID-19. The vector virus delivers important instructions to our cells on how to recognize and fight the virus that causes COVID-19.

• What are the ingredients in the Janssen COVID-19 vaccine?
• What should you mention to your vaccination provider before you get the Janssen COVID-19 vaccine?
• How is the Janssen COVID-19 vaccine given?
• What are the risks of the Janssen COVID-19 vaccine?
• References

These FAQs provide a summary of the most important information about COVID-19 Vaccine, Viral Vector (Janssen). If you would like more information or have any questions, talk to your healthcare provider.

• What is the Novavax COVID-19 Vaccine, Adjuvanted?

  Novavax COVID-19 Vaccine, Adjuvanted is available under emergency use authorization (EUA) to prevent COVID-19 in individuals 12 years of age and older.

  The vaccine is authorized for emergency use to provide:

  • A two-dose primary series to individuals 12 years of age and older.
  • A first booster dose to the following individuals at least 6 months after completion of primary vaccination with an authorized or approved COVID-19 vaccine:
    • Individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate.
    • Individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine.  

  Novavax COVID-19 Vaccine, Adjuvanted contains the SARS-CoV-2 spike protein and Matrix-M adjuvant. Adjuvants are incorporated into some vaccines to enhance the immune response of the vaccinated individual. The spike protein in this vaccine is produced in insect cells; the Matrix M-adjuvant contains saponin extracts from the bark of the Soapbark tree that is native to Chile.

• What should you mention to your vaccination provider before you get the vaccine?
• Who should not get the vaccine?
• How is the vaccine given?
• What are the risks of the vaccine?
• References